WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
Merck (NYSE: MRK) announced groundbreaking results from the Phase 3 ZENITH trial of WINREVAIR™ for pulmonary arterial hypertension (PAH). The study demonstrated a 76% reduction in the risk of major morbidity and mortality events compared to placebo in adults with PAH WHO functional class III or IV at high risk.
At median follow-up of 10.6 months, only 17.4% of WINREVAIR-treated patients experienced major events versus 54.7% in the placebo group. The trial was stopped early due to overwhelming efficacy. Key outcomes included:
- Deaths: 8.1% WINREVAIR vs 15.1% placebo
- Lung transplantation: 1.2% WINREVAIR vs 7.0% placebo
- PAH hospitalizations: 9.0% WINREVAIR vs 50.0% placebo
The safety profile remained consistent with previous studies, with no treatment discontinuations due to adverse events. WINREVAIR is currently approved in over 40 countries based on previous STELLAR trial results.
Merck (NYSE: MRK) ha annunciato risultati straordinari dal trial di Fase 3 ZENITH di WINREVAIR™ per l'ipertensione arteriosa polmonare (PAH). Lo studio ha dimostrato una riduzione del 76% del rischio di eventi di grave morbilità e mortalità rispetto al placebo in adulti con PAH di classe funzionale III o IV ad alto rischio.
Con un follow-up mediano di 10,6 mesi, solo il 17,4% dei pazienti trattati con WINREVAIR ha sperimentato eventi maggiori rispetto al 54,7% del gruppo placebo. Il trial è stato interrotto anticipatamente a causa dell'efficacia travolgente. I risultati chiave includevano:
- Decessi: 8,1% WINREVAIR vs 15,1% placebo
- Trapianto di polmone: 1,2% WINREVAIR vs 7,0% placebo
- Ospedalizzazioni per PAH: 9,0% WINREVAIR vs 50,0% placebo
Il profilo di sicurezza è rimasto coerente con studi precedenti, senza interruzioni del trattamento a causa di eventi avversi. WINREVAIR è attualmente approvato in oltre 40 paesi sulla base dei risultati del precedente trial STELLAR.
Merck (NYSE: MRK) anunció resultados innovadores del ensayo de Fase 3 ZENITH de WINREVAIR™ para la hipertensión arterial pulmonar (HAP). El estudio demostró una reducción del 76% en el riesgo de eventos de morbilidad y mortalidad mayores en comparación con el placebo en adultos con HAP de clase funcional III o IV en alto riesgo.
Con un seguimiento mediano de 10,6 meses, solo el 17,4% de los pacientes tratados con WINREVAIR experimentaron eventos mayores frente al 54,7% en el grupo placebo. El ensayo se detuvo anticipadamente debido a su eficacia abrumadora. Los resultados clave incluyeron:
- Muertes: 8,1% WINREVAIR vs 15,1% placebo
- Transplante de pulmón: 1,2% WINREVAIR vs 7,0% placebo
- Hospitalizaciones por HAP: 9,0% WINREVAIR vs 50,0% placebo
El perfil de seguridad se mantuvo consistente con estudios previos, sin interrupciones del tratamiento debido a eventos adversos. WINREVAIR está actualmente aprobado en más de 40 países basándose en los resultados del ensayo previo STELLAR.
머크 (NYSE: MRK)는 폐동맥 고혈압(PAH)을 위한 WINREVAIR™의 3상 ZENITH 시험에서 획기적인 결과를 발표했습니다. 이 연구는 고위험 PAH 환자 중 WHO 기능 분류 III 또는 IV에 해당하는 성인에서 위약에 비해 주요 이환율 및 사망 사건의 위험을 76% 감소시켰습니다.
중간 추적 관찰 기간이 10.6개월인 가운데, WINREVAIR 치료를 받은 환자 중 17.4%만이 주요 사건을 경험한 반면, 위약 그룹에서는 54.7%가 경험했습니다. 이 시험은 압도적인 효능으로 인해 조기에 중단되었습니다. 주요 결과는 다음과 같습니다:
- 사망: WINREVAIR 8.1% vs 위약 15.1%
- 폐 이식: WINREVAIR 1.2% vs 위약 7.0%
- PAH 입원: WINREVAIR 9.0% vs 위약 50.0%
안전성 프로필은 이전 연구와 일치했으며, 부작용으로 인한 치료 중단은 없었습니다. WINREVAIR는 현재 이전 STELLAR 시험 결과를 바탕으로 40개국 이상에서 승인되었습니다.
Merck (NYSE: MRK) a annoncé des résultats révolutionnaires de l'essai de Phase 3 ZENITH de WINREVAIR™ pour l'hypertension artérielle pulmonaire (HAP). L'étude a démontré une réduction de 76% du risque d'événements majeurs de morbidité et de mortalité par rapport au placebo chez des adultes atteints de HAP de classe fonctionnelle III ou IV à haut risque.
Avec un suivi médian de 10,6 mois, seulement 17,4% des patients traités par WINREVAIR ont connu des événements majeurs contre 54,7% dans le groupe placebo. L'essai a été arrêté prématurément en raison d'une efficacité écrasante. Les résultats clés comprenaient:
- Décès : 8,1% WINREVAIR vs 15,1% placebo
- Transplantation pulmonaire : 1,2% WINREVAIR vs 7,0% placebo
- Hospitalisations pour HAP : 9,0% WINREVAIR vs 50,0% placebo
Le profil de sécurité est resté cohérent avec les études précédentes, sans interruptions de traitement dues à des événements indésirables. WINREVAIR est actuellement approuvé dans plus de 40 pays sur la base des résultats de l'essai précédent STELLAR.
Merck (NYSE: MRK) hat bahnbrechende Ergebnisse aus der Phase-3-Studie ZENITH zu WINREVAIR™ bei pulmonaler arterieller Hypertonie (PAH) bekannt gegeben. Die Studie zeigte eine 76%ige Reduktion des Risikos schwerer Morbiditäts- und Mortalitätsereignisse im Vergleich zur Placebo-Gruppe bei Erwachsenen mit PAH der funktionellen Klassen III oder IV mit hohem Risiko.
Bei einer medianen Nachbeobachtungszeit von 10,6 Monaten erlebten nur 17,4% der mit WINREVAIR behandelten Patienten schwere Ereignisse im Vergleich zu 54,7% in der Placebogruppe. Die Studie wurde vorzeitig aufgrund überwältigender Wirksamkeit abgebrochen. Wichtige Ergebnisse umfassten:
- Todesfälle: 8,1% WINREVAIR vs 15,1% Placebo
- Lungentransplantationen: 1,2% WINREVAIR vs 7,0% Placebo
- Krankenhausaufenthalte wegen PAH: 9,0% WINREVAIR vs 50,0% Placebo
Das Sicherheitsprofil blieb konsistent mit früheren Studien, ohne Unterbrechungen der Behandlung aufgrund von Nebenwirkungen. WINREVAIR ist derzeit in über 40 Ländern auf der Grundlage der Ergebnisse der vorherigen STELLAR-Studie zugelassen.
- 76% reduction in major morbidity and mortality events
- Significant reduction in PAH hospitalizations (9% vs 50%)
- Lower death rates compared to placebo (8.1% vs 15.1%)
- First PAH trial stopped early due to overwhelming efficacy
- No treatment discontinuations due to adverse events
- Key secondary endpoint of overall survival did not reach statistical significance
- Higher rate of bleeding events in treatment group (62.8% vs 34.9%)
- Increased adverse events in treatment group (65.1% vs 32.6%)
Insights
The Phase 3 ZENITH trial results for WINREVAIR represent an exceptional clinical breakthrough in pulmonary arterial hypertension treatment. The 76% reduction in the composite of mortality and major morbidity events is remarkable, particularly in high-risk WHO functional class III/IV patients already on maximum background therapy.
This trial stands out for three crucial reasons: First, it's the first PAH trial stopped early for overwhelming efficacy, a rare occurrence signaling extraordinary results. Second, it used hard clinical endpoints (death, transplantation, hospitalization) rather than surrogate markers. Third, each component of the primary endpoint showed consistent benefit, with hospitalizations for PAH reduced from 50% to just 9% in the treatment arm.
While the secondary endpoint of overall survival didn't reach the heightened statistical threshold required at interim analysis, the directional benefit was clear (HR=0.42). The safety profile remained consistent with previous studies, with manageable side effects primarily including non-serious bleeding events and telangiectasia.
Most significantly, these results expand on the already-established efficacy from the STELLAR trial that led to approvals in 40+ countries, now demonstrating compelling benefit in higher-risk patients. The early stopping of another Phase 3 study (HYPERION) suggests a pattern of strong efficacy across PAH patient populations, potentially establishing WINREVAIR as a practice-changing foundation therapy for this severe condition.
Merck's WINREVAIR just delivered what pharmaceutical companies dream of: a trial stopped early due to "overwhelming efficacy" with a 76% risk reduction in hard clinical endpoints. For context, achieving a 30-40% reduction would typically be considered successful in PAH trials.
This represents a significant commercial opportunity strengthening Merck's cardiovascular/pulmonary portfolio. PAH requires lifelong therapy, and with WINREVAIR already approved in 40+ countries from previous trials, these results should expand its label to higher-risk patients and drive adoption among physicians.
The commercial value of these results is magnified by several factors: First, PAH patients with functional class III/IV have few effective treatment options, creating significant unmet need. Second, demonstrating efficacy in patients already on maximum tolerated therapy positions WINREVAIR as an additive treatment on top of existing regimens. Third, the consistent benefit across mortality and hospitalization endpoints provides compelling evidence for payers.
Additionally, the early stopping of the HYPERION trial in newly diagnosed patients suggests efficacy across the PAH spectrum, potentially making WINREVAIR foundational across treatment paradigms. While exact market sizing wasn't disclosed, specialty drugs for severe conditions like PAH typically command premium pricing, and WINREVAIR's demonstrated clinical benefits position it for strong market uptake and reimbursement support.
WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who are on maximum tolerated background PAH therapy
ZENITH results presented today at ACC.25 as a late-breaking oral presentation and simultaneously published in the New England Journal of Medicine
These results were presented today as a late-breaking oral presentation at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.25) and simultaneously published in the New England Journal of Medicine. These results follow Merck’s announcement in November 2024 that, based on the recommendation of an independent data monitoring committee, the ZENITH study was stopping early due to overwhelming efficacy, and study participants were offered the opportunity to receive WINREVAIR through the SOTERIA open-label extension study.
“The ZENITH study represents the first PAH clinical trial with a primary endpoint comprised entirely of major outcome measures – all-cause death, lung transplantation and hospitalization for PAH,” said Dr. Marc Humbert, Department of Respiratory and Intensive Care Medicine Hospital Bicêtre (AP-HP), University Paris-Saclay and Inserm Unit 999. “WINREVAIR had a significant and clinically meaningful impact on the composite of these outcomes, and together with the growing body of evidence from the clinical development program, these data support the practice-changing potential of WINREVAIR for a broad range of patients with PAH.”
“The impressive results from ZENITH demonstrated that patients on WINREVAIR had a 76 percent risk reduction in the composite of all-cause death, lung transplantation and hospitalization for PAH compared to placebo, with improvement observed early in treatment and increasing benefit throughout the study,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “These results led to the ZENITH study being the first PAH clinical trial stopped early due to overwhelming efficacy, representing an important milestone in clinical research with promise for the PAH community.”
In this trial stopped early due to overwhelming efficacy demonstrated in the primary endpoint, the key secondary endpoint of overall survival did not reach the heightened threshold (p<0.0021) that was required to establish statistical significance at the interim analysis (HR=0.42 [
ZENITH is the second Phase 3 study of WINREVAIR to demonstrate efficacy in adults with PAH. The first was the Phase 3 STELLAR trial previously presented at ACC.23. Results from the ZENITH trial will be shared with regulatory authorities around the world. WINREVAIR is currently approved in more than 40 countries based on the results from the STELLAR trial.
Merck announced in January 2025 that the Phase 3 HYPERION study evaluating WINREVAIR when added to background PAH therapy in newly diagnosed patients with PAH FC II or III at intermediate or high risk of disease progression was stopping early and moving directly to final analysis. The decision to stop the HYPERION study prior to its scheduled completion and offer patients the opportunity to receive WINREVAIR through the SOTERIA open-label extension study was based on the positive results from the interim analysis of the ZENITH trial and a review of the totality of data from the WINREVAIR clinical program to date. Findings from the HYPERION study will be available later this year and presented at a future medical congress.
Study design and additional data from the ZENITH trial
The ZENITH trial (NCT04896008) is a pivotal Phase 3 multicenter, double-blind, placebo-controlled trial evaluating WINREVAIR versus placebo for the treatment of adult patients with WHO FC III or IV PAH at high risk of mortality who were on maximum tolerated background PAH therapy. The primary outcome measure was time to first confirmed morbidity or mortality event, with events defined as all-cause death, lung transplantation or PAH worsening-related hospitalization of ≥24 hours. Secondary outcome measures include overall survival, transplant-free survival and several additional measures.
The trial enrolled 172 participants receiving the maximum tolerated background PAH therapy, who were randomized in a 1:1 ratio to receive either WINREVAIR (n=86) once every 3 weeks at a dose of 0.3 mg/kg at visit 1 and a dose of 0.7 mg/kg thereafter or placebo (n=86). The study population characteristics were: mean [±SD] 54.4 ± 14.3 years of age;
When examined as standalone outcomes, each component of the primary composite endpoint was directionally consistent with the overall treatment effect. There were seven deaths in the WINREVAIR arm (
The safety profile of WINREVAIR was generally consistent with that observed in previous studies. In the ZENITH trial, no patients treated with WINREVAIR discontinued treatment due to an adverse event. Serious adverse events occurred in
All participants who have completed the ZENITH trial were offered the opportunity to receive WINREVAIR as part of the open-label, long-term extension trial, SOTERIA (NCT04796337), consistent with that trial’s eligibility criteria.
About WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics.
WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.
Selected Safety Information for WINREVAIR in the
WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.
WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm3. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required.
In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in
WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.
Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.
The most common adverse reactions occurring in the phase 3 clinical trial (≥
Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.
About PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the
About Merck
At Merck, known as MSD outside of
Forward-Looking Statement of Merck & Co., Inc.,
This news release of Merck & Co., Inc.,
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Please see Prescribing Information for WINREVAIR (sotatercept-csrk) at http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf, Patient Information for WINREVAIR at http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ppi.pdf, and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) at https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ifu_1-vial_2-vial_kits.pdf.
*World Health Organization |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331242477/en/
Media Contacts:
Julie Cunningham
(617) 519-6264
Courtney Ronaldo
(908) 442-5695
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583
Source: Merck Sharp & Dohme